Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT071 in Relapsed/Refractory Multiple Myeloma or Primary Plasma Cell Leukemia
NCT05838131Phase 1Active, not recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Apr 2023
- Primary completion
- Jul 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT071 in multiple myeloma (MM) and plasma cell leukemia (PCL), sponsored by Shanghai Changzheng Hospital. Primary endpoints: Dose-Limiting Toxicity, Adverse Events of Neurotoxicity and Cytokine Release Syndrome at 12 months and 1 more. Started Apr 2023; status: active, not recruiting.
02
Drugs
CT071
03
Conditions
multiple myeloma (MM)plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT05838131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05838131.